Education

University of Minnesota – Twin Cities, 1997, BA, Psychology; 2002, PhD, Clinical Psychology

Professional Area(s)

Psychiatry, Neuroscience, PET imaging, radiotracer development, human imaging, addiction, neuroimmune

Citation

For seminal contributions using state-of-the-art PET brain imaging to identify neuroadaptations in the brains of individuals recovering from addiction and for pioneering the development of innovative neuroimaging paradigms to measure brain function in people managing addiction and other psychiatric disorders.

Education

UConn, 1985, BS, Mechanical Engineering; 1987, MS, Mechanical Engineering; 1995, PhD, Mechanical Engineering

Professional Area(s)

Combustion, fluid mechanics, atomization, combustion instabilities, unsteady flows, active control, propulsion systems, fuel injection, low-emission combustor design, alternate/sustainable fuels

Citation

For outstanding technical leadership of research efforts in the fields of gas turbine combustion, atomization and combustion instabilities, spray diagnostics and outstanding engagement with the broader technical community for developing new technologies that elevate the state-of-the-art and RTX products.

Education

Fudan University (Shanghai), 2006, BS, Chemistry; Brown University, 2009, MSc, Biomedical Engineering; 2010, PhD, Nanomaterials and Nanomedicine

Professional Area(s)

Nanotechnology and In-Space Bioengineering

Citation

For invention of Janus base nanomaterials, the first-of-its-kind rod-shaped delivery technology, specifically designed for penetrating “difficult-to-penetrate” articular cartilage and solid tumors. Pioneering in bioengineering research conducted on the International Space Station, focusing on transformational biomedical applications utilizing microgravity in low-Earth orbit.

Education

Jadavpur University (Calcutta), 1992, BChE , Chemical Engineering; Indian Institute of Science (Bangalore), 1996, MSChE, Chemical Engineering; New Jersey Institute of Technology, 2000, PhD, Mechanical Engineering

Professional Area(s)

Development of physics-based multi-scale (quantum, molecular, and machine-scale) or AI/Machine Learning based computer models for pharmaceutical manufacturing processes and drug delivery; solving powder technology-related problems such as unreliable powder flow, turbocharging, mixing/segregation, 3D printing, and heat transfer

Citation

Internationally acclaimed for the development of experimentally validated multi-scale computer model for novel pharmaceutical manufacturing processes (batch or continuous manufacturing, 3D printing) of different types of dosage forms (tablets, injectables, inhalers); advanced the fundamental understanding of electrostatic charging and its mitigation to avoid dust explosion, jamming, segregation of particulates.

Education

University of Allahabad (India), 1991, BS, Agricultural Engineering; University of Arkansas, 1994, MS, Biological & Agricultural Engineering; Oklahoma State University, 1997, PhD, Biosystems Engineering

Professional Area(s)

Water quality, watershed management, nonpoint source pollution, conservation practices, ecohydrology, simulation modeling, bmp optimization

Citation

For outstanding achievements in the area of ecohydrology, nonpoint source pollution modeling, and watershed management and outstanding leadership in education, research, and extension impacting sustainable agriculture and food production, health, and environmental sustainability.

Education

Harvard, 1986, BA, Neuroscience; Cornell University Medical College, 1990, MD

Professional Area

Bipolar disorder, other mood disorders and suicide in youths and adults; expertise includes multimodal neuroimaging and translational approaches integrating imaging with genetic, stem cell, clinical and behavioral research to understand brain circuitry and generate strategies for early detection, prevention, and treatment

Citation

For pioneering contributions using multimodal neuroimaging to identify structural and functional brain differences in youth and adults with Bipolar Disorder that revolutionized the view of Bipolar Disorder as a disorder of altered brain development, key for understanding Bipolar Disorder pathophysiology, early identification, treatment, and prevention.

Education

American University of Beirut, 2006, BE, Electrical & Computer Engineering; 2007, ME, Electrical & Computer Engineering; University of Illinois at Urbana-Champaign, 2010, PhD, Electrical and Computer Engineering

Professional Area(s)

Power electronics, power converters, electric motor drives, microgrids, electrified transportation, fault diagnostics, fault tolerance, energy systems

Citation

For outstanding technical contributions in the area of fault-tolerant and efficient power electronic systems, especially inverters, electric machines, and controllers, with applications in electrified transportation, microgrids, and renewable energy systems.

John Kadow is a medicinal chemist with considerable experience as a drug hunter in the pharmaceutical industry. Most recently he served as Senior Director of Medicinal Chemistry at ViiV Healthcare where he led a team of medicinal chemists who helped produce drug candidates aimed at improving the lives of people living with HIV. Prior to that, he worked at Bristol-Myers Squibb Co. where he reached the position of Group Director of Medicinal Chemistry and co-led teams in the virology and oncology therapeutic areas which progressed more than ten compounds to the development organization including two that realized approvals. John was a member of a BMS Team who received a PhRMA 2014 Research & Hope Award for Excellence in Biopharmaceutical Research for the discovery and early development of an HIV attachment inhibitor.

He became a member of the Connecticut Academy of Science and Engineering (CASE) in 2015 and is currently serving a two-year term as president that began in July of 2022. John is a co-inventor on more than 135 patent applications and a co-author on many peer-reviewed publications. Prior to joining the pharmaceutical industry, John did postdoctoral research in synthetic chemistry at Yale University in New Haven, CT. John received his PhD in Synthetic Organic Chemistry from Wayne State University in Detroit, MI, and a BA in chemistry from Hope College in Holland, MI.

Craig Crews is a pioneering researcher who launched the pharmaceutical field of Targeted Protein Degradation (TPD). Described as an exceptionally creative scientist, with an eagerness to ask piercing, mechanism-based questions, and a commitment to evidence-based, first-rate, definitive science, he has had a profound translational impact in drug development.

Since 2001, Dr. Crews has developed a new technology, known as PROTACs, or Proteolysis Targeting Chimeras.  This innovative and potentially disruptive approach for inhibiting the function of disease-causing proteins is being commercialized in the biotechnology, New Haven-based, oncology-focused company Arvinas that he founded in 2013. The company focuses on drugs to treat cancer, neurodegeneration, and other diseases [now in clinical trials for breast and prostate cancer].

Crews earned a BA in Chemistry from the University of Virginia, completed a research fellowship at the University of Tübingen (Germany), and received his PhD in biochemistry from Harvard University. His awards and honors are numerous, including the 2013 CURE Entrepreneur of the Year Award, 2014 Ehrlich Award for Medicinal Chemistry, 2015 Yale Cancer Center Translational Research Prize, a NIH R35 Outstanding Investigator Award (2015), elected a CASE Member (2015), the American Association for Cancer Research Award for Chemistry in Cancer Research (2017), Khorana Prize from the Royal Society of Chemistry (2018), Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019), the Heinrich Wieland Prize (2020) and the Scheele Prize (2021).